Profile data is unavailable for this security.
About the company
Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.
- Revenue in CNY (TTM)1.94bn
- Net income in CNY941.49m
- Incorporated1998
- Employees2.14k
- LocationJoinn Laboratories China Co LtdA5 Rongjing East StreetEconomic-Technological Development AreaBEIJING 100176ChinaCHN
- Phone+86 1 067869582
- Fax+86 1 067869966
More ▼
Mergers & acquisitions
| Acquired company | 603127:SHH since announced | Transaction value |
|---|---|---|
| Guangxi Weimei Bio-Tech Co Ltd | -31.01% | 147.13m |
| Yunnan Yinmore Bio-Tech Co Ltd | -31.01% | 125.23m |
Data delayed at least 15 minutes, as of Feb 03 2023 07:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3SBio Inc | 7.42bn | 1.99bn | 20.46bn | 5.16k | 11.46 | 1.46 | 8.67 | 2.76 | 0.7319 | 0.7319 | 2.72 | 5.74 | 0.326 | 1.54 | 5.53 | 1,402,367.00 | 8.59 | 7.42 | 10.81 | 9.00 | 82.52 | 81.85 | 26.35 | 21.79 | 4.32 | -- | 0.2104 | 9.83 | 14.22 | 17.94 | 97.57 | 18.30 | 19.71 | -- |
| China Traditional Chinese Med Hldg CoLtd | 19.60bn | 1.65bn | 20.90bn | 17.36k | 12.66 | 0.9051 | 7.09 | 1.07 | 0.3279 | 0.3279 | 3.89 | 4.59 | 0.4574 | 1.24 | 2.49 | 1,146,444.00 | 4.18 | 5.78 | 6.63 | 8.58 | 58.15 | 59.57 | 9.15 | 12.74 | 1.11 | 13.18 | 0.2394 | 25.20 | 28.68 | 23.87 | 16.21 | 14.86 | 34.02 | 4.93 |
| Keymed Biosciences Inc | 245.12m | -295.34m | 21.62bn | 474.00 | -- | 5.09 | -- | 88.22 | -5.93 | -5.93 | 1.54 | 15.17 | 0.0784 | 0.6746 | 66.81 | 754,207.60 | -9.68 | -- | -10.61 | -- | 90.61 | -- | -123.50 | -- | 10.12 | -- | 0.0397 | -- | -- | -- | -374.88 | -- | -- | -- |
| InnoCare Pharma Ltd | 1.38bn | -345.61m | 27.24bn | 822.00 | -- | 3.46 | -- | 19.68 | -0.2442 | -0.2442 | 0.9831 | 4.25 | 0.1624 | 8.78 | 25.02 | 1,919,715.00 | -4.10 | -- | -4.26 | -- | 90.01 | -- | -25.22 | -- | 21.01 | -- | 0.1879 | -- | 76,368.70 | -- | 83.51 | -- | -- | -- |
| Cansino Biologics Inc | 3.34bn | 1.15bn | 27.80bn | 2.19k | 14.79 | 1.90 | 21.16 | 8.31 | 4.66 | 4.66 | 13.52 | 36.28 | 0.2579 | 1.15 | 5.66 | 1,718,070.00 | 8.87 | 7.06 | 12.44 | 8.33 | 65.65 | -- | 34.38 | 26.65 | 2.59 | -- | 0.2055 | 17.07 | 23,086.49 | -- | 582.65 | -- | 57.01 | -- |
| Simcere Pharmaceutical Group Ltd | 6.50bn | 1.18bn | 31.61bn | 6.54k | 26.30 | 4.40 | 21.50 | 4.86 | 0.4517 | 0.4517 | 2.49 | 2.70 | 0.5611 | 3.75 | 2.72 | 1,052,095.00 | 10.12 | -- | 15.22 | -- | 78.84 | -- | 18.03 | -- | 1.67 | -- | 0.1975 | -- | 10.89 | -- | 125.10 | -- | -- | -- |
| Zai Lab Ltd | 1.54bn | -4.65bn | 31.97bn | 1.95k | -- | 3.61 | -- | 20.73 | -4.87 | -4.87 | 1.61 | 9.04 | 0.1299 | 3.59 | 8.07 | -- | -39.16 | -- | -42.96 | -- | 61.96 | -- | -301.41 | -656.13 | 7.59 | -- | 0.00 | -- | 194.77 | -- | -161.98 | -- | 53.42 | -- |
| AIM Vaccine Co Ltd | -100.00bn | -100.00bn | 32.70bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.14 | -- | -282.65 | -- | -- | -- |
| Joinn Laboratories China Co Ltd | 2.05bn | 903.26m | 36.61bn | 2.28k | 23.71 | 2.48 | 35.33 | 17.86 | 1.69 | 1.69 | 3.83 | 16.14 | 0.19 | 1.23 | 9.01 | 958,191.60 | 8.36 | -- | 10.69 | -- | 48.04 | -- | 43.99 | -- | 1.74 | -- | 0.0119 | -- | 40.97 | -- | 78.13 | -- | -- | -- |
| Akeso Inc | 303.28m | -1.49bn | 41.13bn | 2.29k | -- | 13.14 | -- | 135.61 | -1.83 | -1.83 | 0.3719 | 3.72 | 0.0532 | 0.2873 | 1.02 | 162,615.70 | -30.75 | -- | -36.86 | -- | 76.91 | -- | -578.04 | -- | 2.40 | -148.90 | 0.3322 | -- | -- | -- | -3.72 | -- | -- | -- |
| RemeGen Co Ltd | 1.66bn | 322.04m | 51.83bn | 2.12k | 103.70 | 8.50 | 112.07 | 31.22 | 0.6726 | 0.6726 | 3.41 | 8.20 | 0.3441 | 0.3877 | 403.94 | 782,597.60 | 6.68 | -- | 7.64 | -- | 95.28 | -- | 19.40 | -- | 3.28 | 53.14 | 0.029 | -- | -- | -- | 139.59 | -- | -- | -- |
Data as of Feb 03 2023. Currency figures normalised to Joinn Laboratories China Co Ltd's reporting currency: Hong Kong Dollar HKD
30.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management (Hong Kong) Ltd.as of 17 Jan 2023 | 5.43m | 6.39% |
| Abrdn Asia Ltd.as of 31 Dec 2022 | 4.63m | 5.45% |
| APG Asset Management NVas of 31 Aug 2022 | 4.18m | 4.92% |
| JPMorgan Asset Management (Asia Pacific) Ltd.as of 25 Feb 2022 | 2.38m | 2.81% |
| UBS Asset Management (Japan) Ltd.as of 17 Jan 2023 | 2.22m | 2.61% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2022 | 1.69m | 1.99% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2022 | 1.55m | 1.82% |
| The Vanguard Group, Inc.as of 05 Jan 2023 | 1.44m | 1.69% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2021 | 1.40m | 1.65% |
| UBS Asset Management Switzerland AGas of 17 Jan 2023 | 1.04m | 1.22% |
More ▼
Data from 30 Jun 2022 - 30 Nov 2022Source: FactSet Research Systems Inc.
